# of Displayed Technologies: 8 / 8

Applied Category Filter (Click To Remove): Antibodies


Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
  • College: OSU Wexner Medical Center
  • Inventors:
  • Licensing Officer: Schultz, Teri

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
  • College: College of Medicine (COM)
  • Inventors: Chu, Nam; Le, Nhat
  • Licensing Officer: Willson, Christopher

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

Potential uses of IgG Fc for treating human diseases
TS-036778 — Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
  • College: College of Medicine (COM)
  • Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
  • College: College of Medicine (COM)
  • Inventors: Palmieri, Dario; Croce, Carlo
  • Licensing Officer: Taysavang, Panya

Loading icon